Literature DB >> 17527074

Positive-block ratio in radical prostatectomy specimens is an independent predictor of prostate-specific antigen recurrence.

Rebecca A Marks1, Haiqun Lin, Michael O Koch, Liang Cheng.   

Abstract

Tumor volume has been considered an important variable in determining the probability of prostate-specific antigen (PSA) recurrence in prostatic adenocarcinoma. There have been many studies that have tried to determine an appropriate method of calculating tumor volume, but no single methodology has been agreed upon. We tested the hypothesis that the ratio of tumor positive tissue blocks to the total number of blocks submitted (positive-block ratio) can be used as an independent prognostic indicator for PSA recurrence. We analyzed 504 patients who underwent total radical retropubic prostatectomy between 1990 and 1998. None of the patients had preoperative radiation or androgen-deprivation therapy. Clinical records were reviewed. The mean positive-block ratio was 0.44 (median, 0.43; range, 0.05 to 1.0). The positive block-ratio was significantly associated with Gleason score, pathologic stage, surgical margin status, extraprostatic extension, seminal vesical invasion, lymph node metastasis, perineural invasion, and preoperative serum PSA level (all P<0.001). Using a multivariate Cox regression model, controlling for pathologic stage, Gleason score, lymph node metastasis, and surgical margin status, positive-block ratio was an independent predictor of PSA recurrence (hazard ratio, 2.3; 95% confidence interval, 1.06-4.83; P=0.03). Five-year PSA recurrence-free survival was 67% for those patients with positive-block ratio <or=0.43, as compared with 42% those with positive-block ratio >0.43 (P<0.001). Positive-block ratio is an independent predictor of PSA recurrence and this simple method of tumor measurement seems to be promising for quantifying tumor volume if our findings are validated by subsequent reports.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17527074     DOI: 10.1097/01.pas.0000213429.61374.4f

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  6 in total

1.  Percent tumor volume predicts biochemical recurrence after radical prostatectomy: multi-institutional data analysis.

Authors:  Cheryn Song; Seongil Seo; Hanjong Ahn; Seok-Soo Byun; Jin Seon Cho; Young Deuk Choi; Eunsik Lee; Hyun Moo Lee; Sang Eun Lee; Han Yong Choi
Journal:  Int J Clin Oncol       Date:  2011-08-05       Impact factor: 3.402

2.  Total intraglandular and index tumor volumes predict biochemical recurrence in prostate cancer.

Authors:  Su-Jin Shin; Cheol Keun Park; Sung Yoon Park; Won Sik Jang; Joo Yong Lee; Young Deuk Choi; Nam Hoon Cho
Journal:  Virchows Arch       Date:  2016-06-15       Impact factor: 4.064

3.  In Organ-confined Prostate Cancer, Tumor Quantitation Not Found to Aid in Prediction of Biochemical Recurrence.

Authors:  Yujiro Ito; Emily A Vertosick; Daniel D Sjoberg; Andrew J Vickers; Hikmat A Al-Ahmadie; Ying-Bei Chen; Anuradha Gopalan; Sahussapont J Sirintrapun; Satish K Tickoo; James A Eastham; Peter T Scardino; Victor E Reuter; Samson W Fine
Journal:  Am J Surg Pathol       Date:  2019-08       Impact factor: 6.394

Review 4.  Pathologic basis of focal therapy for early-stage prostate cancer.

Authors:  Vladimir Mouraviev; Janice M Mayes; Thomas J Polascik
Journal:  Nat Rev Urol       Date:  2009-04       Impact factor: 14.432

5.  Effect of serum testosterone and percent tumor volume on extra-prostatic extension and biochemical recurrence after laparoscopic radical prostatectomy.

Authors:  Eu Chang Hwang; Seong Hyeon Yu; Yang Hyun Jo; Seung Il Jung; Taek Won Kang; Dong Deuk Kwon; Chan Choi; Suk Hee Heo; Jun Eul Hwang; Sung-Hoon Jung; Tae-Young Jung
Journal:  Asian J Androl       Date:  2016 Jan-Feb       Impact factor: 3.285

6.  Can Tumour Volume Percentage in Radical Prostatectomy Predict Cancer Biochemical Recurrence? Determining a Cut-off Point and Composite Risk Factors Approach.

Authors:  Ahmad Alenezi; Mohamed Ismail; Christopher Eden
Journal:  Res Rep Urol       Date:  2021-06-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.